~~<i id='6DFCEAE5FC'><strike id='6DFCEAE5FC'><tt id='6DFCEAE5FC'><pre id='6DFCEAE5FC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：entertainment 2025-08-11 02:16:11 - browse：4732

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Food makers to regulators: Ultra

Wikipedia

focus

entertainment

focus

explore

OLIVIERDOULIERY/AFPviaGettyImagesMedicalstudentsexperiencesignificantmentaldistress,includinghighrat

WSS

Ukraine and a new approach to mental health in war

FDA panel to weigh approval of NurOwn, controversial ALS drug

CDC advisers recommend seasonal use of Pfizer RSV shot

EpiPen alternative approval delay highlights citizen petition issue

How Vertex's cystic fibrosis drug is changing patients' lives

Microbiome research is starting to find links to chronic diseases

hotspot

fashion

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

Senate HELP committee spars over health care workforce policies

What does generative AI mean for health care? We asked experts

Senators: Long

Medicare details structure of new drug price negotiation program

How housing is health care on Long Island

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

23andMe had bad news about my health. I wish a person had delivered it

Ukraine and a new approach to mental health in war

focus

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Lasker Awards 2023: Winners in biomedical research

How medical schools plan to diversify without affirmative action

Second xenotransplant done with gene

White House touts steps to stem shortages of cancer treatments

How to make the FDA’s new prescription one

entertainment

focus

focus

explore